Halozyme (RV7) Stock Statistics & Valuation Metrics
Total Valuation
Halozyme has a market cap or net worth of EUR 13.02B. The enterprise value is EUR 11.40B.
- Market Cap
- EUR 13.02B
- Enterprise Value
- EUR 11.40B
Share Statistics
Halozyme has 113,498,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 113,498,000
- Owned by Insiders
- 0.92%
- Owned by Institutions
- 67.71%
Financial Efficiency
Halozyme’s return on equity (ROE) is 6.49 and return on invested capital (ROIC) is 23.20%.
- Return on Equity (ROE)
- 6.49
- Return on Assets (ROA)
- 0.13
- Return on Invested Capital (ROIC)
- 23.20%
- Return on Capital Employed (ROCE)
- 0.34
- Revenue Per Employee
- 3.30M
- Profits Per Employee
- 749.15K
- Employee Count
- 423
- Asset Turnover
- 0.55
- Inventory Turnover
- 1.30
Valuation Ratios
The current PE Ratio of Halozyme is 36.54. Halozyme’s PEG ratio is -1.71.
- PE Ratio
- 36.54
- PS Ratio
- 8.77
- PB Ratio
- 105.08
- Price to FCF
- 18.11
- Price to Operating Cash Flow
- 18.43
- PEG Ratio
- -1.71
Income Statement
In the last 12 months, Halozyme had revenue of 1.40B and earned 316.89M in profits. Earnings per share was 2.64.
- Revenue
- 1.40B
- Gross Profit
- 1.17B
- Operating Income
- 802.59M
- Pretax Income
- 466.88M
- Net Income
- 316.89M
- EBITDA
- 573.05M
- Earnings Per Share (EPS)
- 2.64
Cash Flow
In the last 12 months, operating cash flow was 818.60M and capital expenditures -12.37M, giving a free cash flow of 806.22M billion.
- Operating Cash Flow
- 818.60M
- Free Cash Flow
- 806.22M
- Free Cash Flow per Share
- 6.87
Dividends & Yields
Halozyme pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 5.52%
- Earnings Yield
- 2.74%
Stock Price Statistics
- Beta
- 0.31
- 52-Week Price Change
- 107.13%
- 50-Day Moving Average
- 99.79
- 200-Day Moving Average
- 72.30
- Relative Strength Index (RSI)
- 67.94
- Average Volume (3m)
- 109
Important Dates
Halozyme upcoming earnings date is Nov 05, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Halozyme as a current ratio of 4.66, with Debt / Equity ratio of 4389.38%
- Current Ratio
- 4.66
- Quick Ratio
- 3.66
- Debt to Market Cap
- 0.27
- Net Debt to EBITDA
- 3.51
- Interest Coverage Ratio
- 44.28
Taxes
In the past 12 months, Halozyme has paid 149.99M in taxes.
- Income Tax
- 149.99M
- Effective Tax Rate
- 0.32
Enterprise Valuation
Halozyme EV to EBITDA ratio is 23.08, with an EV/FCF ratio of 20.57.
- EV to Sales
- 9.97
- EV to EBITDA
- 23.08
- EV to Free Cash Flow
- 20.57
- EV to Operating Cash Flow
- 20.25
Balance Sheet
Halozyme has EUR 231.00M in cash and marketable securities with EUR 2.15B in debt, giving a net cash position of -EUR 1.92B billion.
- Cash & Marketable Securities
- EUR 231.00M
- Total Debt
- EUR 2.15B
- Net Cash
- -EUR 1.92B
- Net Cash Per Share
- -EUR 16.88
- Tangible Book Value Per Share
- -EUR 11.60
Margins
Gross margin is 82.42%, with operating margin of 55.95%, and net profit margin of 24.86%.
- Gross Margin
- 82.42%
- Operating Margin
- 55.95%
- Pretax Margin
- 35.06%
- Net Profit Margin
- 24.86%
- EBITDA Margin
- 43.18%
- EBIT Margin
- 36.28%
Analyst Forecast
The average price target for Halozyme is EUR 94.78, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 94.78
- Price Target Upside
- 18.61% Downside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- 31.83%
- EPS Growth Forecast
- -26.61%
Scores
- Smart Score
- 8
- AI Score
- ―
